Hegelei Pharmaceutical Constructs Plant In Dalian
This article was originally published in PharmAsia News
Executive Summary
Hegelei Dalian Pharmaceutical recently commenced construction on its RMB 803 million ($117 million) project on Dalian's Changxing island. On a site measuring 200,000 square meters, the company will finish the first phase of construction on its plant this October, complete manufacturing facilities installation and testing this December, and go into operation by end of the year. Hegelei has signed a letter of intent with German firm Maxi, a large pharmaceutical business distributing medium- and high-end anti-tumor drugs. The companies will jointly establish the largest clinical research outsourcing base in Liaoning. In addition, Hegelei will act as an agent for Maxi to bring the latter's anti-tumor drugs into China. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.